NRA-0160 is a selectivedopamine D4 receptorantagonist, with aK_ivalue of 0.48 nM and with negligible affinity fordopamine D2 receptor(K_i: >10000 nM),D3 receptor(K_i: 39 nM), rat5-HT2A receptor(K_i: 180 nM) and ratα1 adrenoceptor(K_i: 237 nM).

NRA0160 (0.1, 1, or 3 mg/kg, i.p.) has no effect on PCP-induced hyperlocomotion, stereotypy or ataxia in SD rats. NRA0160, at any dose, does not reduce cumulated counts of locomotion and cumulated scores of stereotypy emerging, and has no effect on extracellular glutamate levels and locomotor activity emerged after saline injection^[1]. NRA0160 dose-dependently and significantly reverses the effects of MAP on both A9 and Al0 dopamine neurons. NRA0160 is slightly more potent in reversiig the effects of MAP on A10 (ED₅₀= 1.0 mg/kg) than on A9 dopamine neurons (ED₅₀= 1.3 mg/kg). NRA0160 reverses the effect of AP0 on both A9 and A10 dopamine neurons. ED₅₀values for the effects of NRA0160 on APO-induced inhibition of A9 and A10 dopamine neurons are 1.3 mg/kg and 0.5 mg/kg, respectively^[2].

439.52

C₂₄H₂₃F₂N₃OS

204718-47-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.